Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,641.00
  • Today's Change-13.00 / -0.79%
  • Shares traded43.23k
  • 1 Year change-35.29%
  • Beta0.1839
Data delayed at least 20 minutes, as of Jul 05 2022 11:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

As of last trade, Hikma Pharmaceuticals PLC (HIK:LSE) traded at 1,641.00, 12.44% above the 52 week low of 1,459.50 set on Jun 22, 2022.
52-week range
Today
1,459.50Jun 22 20222,703.00Aug 03 2021
Markit short selling activity
Low
Med
High
Open1,663.50
High1,667.50
Low1,633.00
Bid1,640.50
Offer1,641.50
Previous close1,654.00
Average volume713.36k
Shares outstanding220.11m
Free float154.52m
P/E (TTM)11.06
Market cap3.64bn GBP
EPS (TTM)1.49
GBP
Annual div (ADY)40.69
GBX
Annual div yield (ADY)2.51%
Div ex-dateMar 17 2022
Div pay-dateApr 28 2022
Data delayed at least 20 minutes, as of Jul 05 2022 11:35 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Buy at 1,897.00 on 24 Feb 2022Read the full article

Board of Directors

1/11

Said Darwazah, Executive Chairman

2/11

Siggi Olafsson, Chief Executive Officer

3/11

Mazen Darwazah, Executive Vice Chairman, President of MENA

4/11

Ali Al-Husry, Non-Executive Director

5/11

Pat Butler, Nomination and Governance Committee Chairman, Senior Independent Non-Executive Director

6/11

Dr. Pamela Kirby, Remuneration Committee Chair, Independent Non-Executive Director

7/11

John Castellani, CREC Chairman, Independent Non-Executive Director

8/11

Nina Henderson, Independent Non-Executive Director

9/11

Cynthia Flowers, Independent Non-Executive Director

10/11

Douglas Hurt, Audit Committee Chairman, Independent Non-Executive Director

11/11

Peter Speirs, Company Secretary

Contact

Address:
Hikma Pharmaceuticals PLC
1 New Burlington Place
London
W1S 2HR

T: +44 (0) 20 7399 2760
F: +44 (0) 20 7399 2761
E: investors@hikma.uk.com
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.